How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Lupus Therapeutic Market
- By Disease Type: Antimalarial Drugs, Corticosteroids, NSAIDs (Nonsteroidal Anti-inflammatory Drugs), Immunosuppressants/Immunomodulators, Calcineurin Inhibitors, Biologics, Other Therapeutics
- By Drug Class: Antimalarial Drugs, Corticosteroids, NSAIDs (Nonsteroidal Anti-inflammatory Drugs), Immunosuppressants/Immunomodulators, Calcineurin Inhibitors, Biologics, Other Therapeutics
- By Route of Administration: Oral, Intravenous (IV), Subcutaneous (SC), Topical
- By End User: Hospitals, Specialty Clinics, Home Care Settings, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antimalarial Drugs leads By Disease Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 308 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Lupus Therapeutic Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Disease Type 7
Drug Class 7
Route of Administration 4
End User 4
Distribution Channel 4
Companies profiled
GSK plc
AstraZeneca plc
F Hoffmann-La Roche Ltd.
Aurinia Pharmaceuticals Inc
Pfizer Inc
Sanofi SA
Bristol Myers Squibb Company
Novartis AG
AbbVie Inc
Merck & Co Inc
Eli Lilly and Company
UCB SA
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GSK plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →F Hoffmann-La Roche Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Aurinia Pharmaceuticals Inc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pfizer Inc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sanofi SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bristol Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AbbVie Inc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Merck & Co Inc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →UCB SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Viatris Inc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Amneal Pharmaceuticals Inc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Johnson & Johnson
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,698M by 2033 · 3.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antimalarial Drugs35.1
- Corticosteroids16.0
- NSAIDs (Nonsteroidal Anti-inflammatory Drugs)9.5
- Immunosuppressants/Immunomodulators6.5
- Calcineurin Inhibitors14.1
- Biologics7.3
- Other Therapeutics11.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$680.8M → $845.5M · 2.7%
Europe$474.5M → $608.6M · 3.2%
Asia Pacific$433.2M → $631.6M · 4.8%
Latin America$268.2M → $317.7M · 2.1%
Middle East and Africa$206.3M → $261.2M · 3.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.362026
3.372027
3.392028
3.402029
3.422030
3.422031
3.442032
3.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GSK plc15.3
- AstraZeneca plc24.1
- F Hoffmann-La Roche Ltd.14.0
- Aurinia Pharmaceuticals Inc9.5
- Pfizer Inc4.3
- Sanofi SA4.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Type25.2%
Drug Class19.7%
Route of Administration14.5%
End User15.2%
Distribution Channel25.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.7
- Europe22.8
- Asia Pacific23.7
- Latin America11.9
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GSK plc | 79 | 99 | 86 | 78 | 99 | 93 | 89 |
| AstraZeneca plc | 82 | 80 | 87 | 74 | 90 | 88 | 84 |
| F Hoffmann-La Roche Ltd. | 80 | 84 | 77 | 87 | 72 | 66 | 78 |
| Aurinia Pharmaceuticals Inc | 82 | 57 | 82 | 71 | 58 | 77 | 71 |
| Pfizer Inc | 63 | 53 | 72 | 72 | 59 | 52 | 62 |
| Sanofi SA | 69 | 57 | 70 | 70 | 69 | 63 | 66 |
| Bristol Myers Squibb Company | 64 | 58 | 41 | 44 | 61 | 41 | 52 |
| Novartis AG | 38 | 37 | 56 | 39 | 37 | 57 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GSK plc
- AstraZeneca plc
- F Hoffmann-La Roche Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GSK plc | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| AstraZeneca plc | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| F Hoffmann-La Roche Ltd. | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Aurinia Pharmaceuticals Inc | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| Pfizer Inc | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Sanofi SA | ✓ | − | − | ✓ | ◐ | ✓ |
| Bristol Myers Squibb Company | ✓ | ◐ | − | ◐ | ◐ | − |
| Novartis AG | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GSK plc89
2AstraZeneca plc84
3F Hoffmann-La Roche Ltd.78
4Aurinia Pharmaceuticals Inc71
5Sanofi SA66
6Pfizer Inc62
7Bristol Myers Squibb Company52
8Novartis AG44
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
GSK plcAstraZeneca plcF Hoffmann-La Roche Ltd.
Challenger1
Strong scale, closing on the leaders.
Aurinia Pharmaceuticals Inc
Contender2
Focused players with pockets of strength.
Pfizer IncSanofi SA
Niche2
Specialists in a single segment or region.
Bristol Myers Squibb CompanyNovartis AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Type in North America, then scale across Lupus Therapeutic Market — a $400M beachhead inside a $6.53B market.
Beachhead (SOM)$400Mobtainable near-term
Serviceable (SAM)$2.56Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Antimalarial Drugs
Best fit — highest urgency & budget in Disease Type.
Economic buyer77 fit
Corticosteroids
Strong fit — clear ROI and a fast path to value.
End user67 fit
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve20%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Disease Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Lupus Therapeutic Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified23%
Evaluation14%
Closed-won5%
$14.9KCAC
$84KLTV
5.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Lupus Therapeutic Market is a high-growth opportunity — $2.21B by 2033, compounding at 10.1%.
TAM · 2025$1.02Btoday
TAM · 2033$2.21Bforecast
CAGR10.1%2027–2033
Cumulative$13.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.21BTotal addressable market
SAM$845MServiceable available market
SOM$175MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Disease Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.21BLarge & growingTAM by 2033 at 10.1% CAGR
$845MServiceable nowreachable with today’s model
$175MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.72BBear6.6% CAGR
$2.21BBase10.1% CAGR
$2.83BBull13.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Lupus Therapeutic Market — a $6.94B market by 2033. Plan: grow share from 11.5% to 19.0%.
Market size · 2033$6.94Btotal addressable
Market CAGR6.6%2027–2033
Target share19.0%from 11.5% today
Revenue ambition$1.32Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.5% | 19.0% | At risk |
| Revenue | $767M | $1.32B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 28.7% | 41.9% | Ahead |
| Customer retention | 89.4% | 94.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $196M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Disease Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Lupus Therapeutic Market conversation — a $9.06B market you can size, segment and defend in minutes.
Market size · 2033$9.06Btotal opportunity
Growth8.8%CAGR to 2033
Addressable buyers1,550+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Type
Goal Grow share in Disease Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 4 mopayback period
$57K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
GSK plcAstraZeneca plcF Hoffmann-La Roche Ltd.Aurinia Pharmaceuticals IncPfizer IncSanofi SABristol Myers Squibb CompanyNovartis AG+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Lupus Therapeutic Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Lupus Therapeutic Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →LVAD Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportLysosomal Storage Diseases Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMale Infertility Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMammography Market
Mammography Market is valued at USD 4.55 Billion in 2025 and is expected to reach USD 5.75 Bill…
$4.6B market · 2025 base year
View reportMammography Equipment Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportIntelligent Prosthetics Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportBox Hearing Aids Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportChemo Pumps Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportSystemic Aspergillosis and Systemic Candidasis Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSystemic Oral Azoles Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportTecentriq Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportRectoscopes Endoscope Market
Market size, share, segmentation and regional forecast.
$905M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.